The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a ...

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new ...

Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...